Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | ACACB | O00763 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15447211 | 0.88 | DDB1 (0.47) | USP2SMN1; SMN2CRBNDDB1KDM4E | |
| SCHEMBL12501315 | 0.86 | USP2 (0.47) | USP2SMN1; SMN2CRBNDDB1KDM4E | |
| SCHEMBL2028457 | 0.85 | DDB1 (0.45) | USP2SMN1; SMN2CRBNDDB1KDM4E | |
| SCHEMBL17608975 | 0.84 | CRBN (0.42) | USP2SMN1; SMN2CRBNDDB1KDM4E | |
| SCHEMBL2769705 | 0.84 | CRBN (0.43) | USP2SMN1; SMN2CRBNDDB1KDM4E | |
| SCHEMBL9950025 | 0.82 | CRBN (0.43) | USP2SMN1; SMN2CRBNDDB1KDM4E | |
| SCHEMBL769732 | 0.81 | USP2 (0.46) | USP2SMN1; SMN2CRBNDDB1KDM4E | |
| SCHEMBL30150136 | 0.81 | ACACB (0.42) | USP2SMN1; SMN2CRBNDDB1KDM4E | |
| SCHEMBL18319196 | 0.81 | USP2 (0.43) | USP2SMN1; SMN2CRBNDDB1KDM4E | |
| SCHEMBL22770531 | 0.80 | USP2 (0.45) | USP2SMN1; SMN2CRBNDDB1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114728938-B | Tetrahydroisoquinoline spiro compounds as PRMT5 inhibitors | 南京再明医药有限公司 | 2024-05-24 | — | — | CN | disclosed |
| US-20030187023-A1 | Sulfone derivatives, process for their production and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-10-02 | — | — | US | disclosed |
| EP-1302462-A1 | SULFONE DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2003-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187023-A1 | Sulfone derivatives, process for their production and use thereof | SULT1E1, RRS1, SHH | USP2 3336/4885SMN1; SMN2 3830/4885CRBN 429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.